256 related articles for article (PubMed ID: 28369673)
1. Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy.
Mei H; Jiang H; Wu Y; Guo T; Xia L; Jin R; Hu Y
Br J Haematol; 2018 Jun; 181(5):689-692. PubMed ID: 28369673
[No Abstract] [Full Text] [Related]
2. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
Chou CK; Turtle CJ
Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
[No Abstract] [Full Text] [Related]
3. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Santomasso BD; Park JH; Salloum D; Riviere I; Flynn J; Mead E; Halton E; Wang X; Senechal B; Purdon T; Cross JR; Liu H; Vachha B; Chen X; DeAngelis LM; Li D; Bernal Y; Gonen M; Wendel HG; Sadelain M; Brentjens RJ
Cancer Discov; 2018 Aug; 8(8):958-971. PubMed ID: 29880584
[TBL] [Abstract][Full Text] [Related]
4. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
5. CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions.
Hunter BD; Jacobson CA
J Natl Cancer Inst; 2019 Jul; 111(7):646-654. PubMed ID: 30753567
[TBL] [Abstract][Full Text] [Related]
6. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
7. CAR-T cell: Toxicities issues: Mechanisms and clinical management.
Wallet F; Sesques P; Devic P; Levrard M; Ader F; Friggeri A; Bachy E
Bull Cancer; 2021 Oct; 108(10S):S117-S127. PubMed ID: 34920794
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities.
Rubinstein JD; Nelson AS; Krupski C; O'Brien W; Taylor JM; Badgett TC; Huang M; Davies SM; Phillips CL
Pediatr Blood Cancer; 2020 Apr; 67(4):e28199. PubMed ID: 32020723
[TBL] [Abstract][Full Text] [Related]
9. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
10. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.
Jiang H; Liu L; Guo T; Wu Y; Ai L; Deng J; Dong J; Mei H; Hu Y
Ann Hematol; 2019 Jul; 98(7):1721-1732. PubMed ID: 31055613
[TBL] [Abstract][Full Text] [Related]
11. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.
Titov A; Petukhov A; Staliarova A; Motorin D; Bulatov E; Shuvalov O; Soond SM; Piacentini M; Melino G; Zaritskey A; Barlev NA
Cell Death Dis; 2018 Sep; 9(9):897. PubMed ID: 30181581
[TBL] [Abstract][Full Text] [Related]
12. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.
Shalabi H; Wolters PL; Martin S; Toledo-Tamula MA; Roderick MC; Struemph K; Kane E; Yates B; Delbrook C; Mackall CL; Lee DW; Fry TJ; Shah NN
J Immunother; 2018 Sep; 41(7):350-358. PubMed ID: 30048343
[TBL] [Abstract][Full Text] [Related]
13. Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
Foster MC; Savoldo B; Lau W; Rubinos C; Grover N; Armistead P; Coghill J; Hagan RS; Morrison K; Buchanan FB; Cheng C; Laing S; Ivanova A; West J; Foster A; Serody J; Dotti G
Blood; 2021 Jun; 137(23):3306-3309. PubMed ID: 33624095
[No Abstract] [Full Text] [Related]
14. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
[TBL] [Abstract][Full Text] [Related]
16. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.
Obstfeld AE; Frey NV; Mansfield K; Lacey SF; June CH; Porter DL; Melenhorst JJ; Wasik MA
Blood; 2017 Dec; 130(23):2569-2572. PubMed ID: 29074500
[No Abstract] [Full Text] [Related]
17. CAR T-cell therapy-related neurotoxicity in paediatric acute lymphocytic leukaemia.
Tan AP
Pediatr Blood Cancer; 2020 Nov; 67(11):e28635. PubMed ID: 32770654
[TBL] [Abstract][Full Text] [Related]
18. Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
[TBL] [Abstract][Full Text] [Related]
19. Toxicities of CAR T-Cell Therapy and the Role of the Consultation-Liaison Psychiatrist.
Pawar DS; Molinaro JR; Knight JM; Heinrich TW
Psychosomatics; 2019; 60(5):519-523. PubMed ID: 30717979
[No Abstract] [Full Text] [Related]
20. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Luskin MR; DeAngelo DJ
Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
